PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that ...

The biotech, which earlier this year laid off nearly all of its staff, also announced a PIPE that will hand it $175 million in new funding.

Vor Bio receives ex-Greater China rights to develop and commercialize telitacicept, a novel, dual-target recombinant fusion protein in global Phase 3 development for generalized myasthenia gravis ...

For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...

The city turned over nearly 4,500 records from Chris Bausch’s personal devices in response to The Tribune’s lawsuit.

Investing.com -- Vor Biopharma Inc (NASDAQ: VOR) stock surged 85% after the company announced an exclusive licensing agreement with China’s RemeGen Co., Ltd. for telitacicept, a novel dual-target ...

The system is structured around a client-server architecture designed to provide scalability, remote accessibility, and ...

Biotech M&A is heating up, making small-cap firms with breakthrough assets top acquisition targets and potential big winners ...

Vor Biopharma Inc. (NASDAQ:VOR) saw its stock surge by 85% after unveiling a major licensing agreement with RemeGen Co., Ltd.